Assessment of the Usefulness of SMI (Superb Vascular Imaging) for the Characterisation of Pancreatic Cystic Tumours (IMAKYST) (IMAKYST)
A cystic lesion is an abnormal cavity formed within tissue or an organ, which may contain a liquid, semi-solid or gaseous substance.
There are different types of pancreatic cystic lesions: lesions that may become cancerous and completely benign lesions that do not require monitoring, such as serous cystadenomas (SCs) and pseudocysts.
Diagnostic difficulties mean that one in three patients with a SC undergoes unnecessary surgery with significant morbidity and mortality (risk of death). Currently, needle-based confocal laser endomicroscopy (nCLE) is the gold standard technique for the diagnosis of SC.
SC is a lesion characterised by an extensive network of small blood vessels present in all the cyst walls and throughout the cyst's peripheral capsule. SMI (Superb Vascular Imaging) is a new ultrasound mode that improves the visibility of blood flow in the vessels without the injection of contrast medium (a diagnostic agent used for certain medical imaging examinations, most often administered intravenously), unlike nCLE.
The Mermoz Endoscopy Centre will be equipped with an ultrasound console enabling SMI to be performed during an echoendoscopy examination. This technology is now available on the new EUS Aplio i800 console (Canon-Olympus), which is CE marked.
To date, no data has been published on the potential of SMI to characterise and diagnose CS. This is why this clinical investigation is being conducted.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Pancreatic cysts are becoming increasingly common in the general population. They are most often discovered incidentally during cross-sectional abdominal imaging.
There are different types of pancreatic cystic lesions, each with distinct risks of progression. Lesions with the potential for malignant transformation are typically mucinous lesions (papillary intraductal mucinous neoplasms of the pancreas [PIMN] and mucinous cystic neoplasms [MCN]), formerly known as mucinous cystadenomas), whereas non-mucinous lesions (serous cystadenomas [SCs] and pseudocysts) are entirely benign and do not require monitoring.
SC typically presents as a solitary cyst with no communication with the Wirsung duct, appearing microcystic with central calcification. This typical appearance is not always present, and SC can mimic a mucinous lesion. In such cases, imaging and echoendoscopy findings are not discriminatory. Histological and biochemical analysis of the fluid obtained during cyst aspiration may be helpful, but the specificity is usually insufficient to make a definitive decision regarding the absence of surgery and the need for monitoring. These diagnostic difficulties mean that one in three patients with SC undergo unnecessary surgery, with significant morbidity and mortality.
There are currently two highly effective techniques for diagnosing SC:
- Endocystic microbiopsy, which has a diagnostic accuracy of nearly 100% but a high complication rate (around 10%). It is no longer recommended except in exceptional cases.
- Needle-based confocal laser endomicroscopy (nCLE), which has 100% specificity for the diagnosis of SC.
SC is a lesion characterised by intense microvascularisation present in all the cyst walls and throughout the entire peripheral capsule of the cyst. SMI is a new ultrasound modality capable of visualising microvascular flow without the need for contrast injection, unlike nCLE.
The Mermoz Endoscopy Centre will be equipped with an ultrasound console enabling SMI to be performed during an echoendoscopy examination. This technology is now available on the new Aplio i800 EUS console (Canon-Olympus).
To date, no data has been published on the potential of SMI for characterising and diagnosing SC. This is why this clinical investigation is being conducted.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Bertrand NAPOLEON, MD
- Número de telefone: + 33 4 78 75 67 43
- E-mail: dr.napoleon@wanadoo.fr
Locais de estudo
-
-
-
Lyon, França, 69008
- Recrutamento
- Hôpital privé Jean Mermoz
-
Contato:
- Bertrand NAPOLEON, MD
- Número de telefone: + 33 4 78 75 67 43
- E-mail: dr.napoleon@wanadoo.fr
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Patient referred for confocal microscopy (nCLE) assessment of a pancreatic cyst of unknown origin
- Patient with a cyst measuring more than 15 mm in diameter and at least one cyst cavity measuring ≥ 5 mm (to allow nCLE to be performed)
- Patient registered with or covered by the National Health Service
- French-speaking patient who has signed an informed consent form
Exclusion Criteria:
- Patient with calcifying chronic pancreatitis
- Presence of a communication with the main pancreatic duct on MRI or endoscopic ultrasound
- Patient whose lesion meets criteria for malignancy (tissue mass, metastases, ascites, vascular infiltration)
- Patient with a contraindication to endoscopic ultrasound-guided puncture (haemostatic disorder)
- Patient with a known allergy to fluorescein (used in nCLE)
- Pregnant woman
- Patient under legal guardianship: adults under guardianship, curatorship or other legal protection, or deprived of their liberty by judicial or administrative order
- Hospitalised patient without consent
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Diagnóstico
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: SMI group
Intervention involves acquiring B-mode images of the pancreatic cyst using SMI
|
B-mode imaging of pancreatic cysts with SMI using the new Aplio i800 EUS console (Canon-Olympus)
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
SMI specificity
Prazo: Day 0
|
SMI specificity is expressed as a percentage.
Specificity is defined as the number of true negatives (negative diagnoses in patients without SC) divided by the total number of patients without SC.
|
Day 0
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- 2026-A00624-47
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .